SecBot SecBot
8-K ·Filed Sep 3, 2026

GTBP

GT Biopharma, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed2mo ago SEC0001493152-26-041333
Actionable Insight • Neutral

The reverse split is a Nasdaq compliance measure for a micro-cap biotech with a $13M market cap. Post-split float of ~1.8M shares is very thin, increasing volatility risk. Monitor for potential Nasdaq bid-price compliance and any subsequent capital raise given the company's multiple active S-1 registration statements. The elimination of 11 preferred series with no shares outstanding is administrative cleanup with no economic impact.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$0.2524
T+0 close · Sep 3, 2026 · via day close
Latest settled
+2316.80%
T+20 · $6.10 · next T+60 in 13d
Vs SPY
+2317.26%
α at T+20
Latest observation
−30.51%
T+51 · FF3 residual α
  1. T+0 · Sep 3 $0.2524entry
  2. T+1 · 2mo ago −4.52%α −4.13% · $0.2410
  3. T+5 · 2mo ago +3311.25%α +3312.40% · $8.61
  4. T+20 · 7w ago +2316.80%α +2317.26% · $6.10
  5. T+51 · todayOpen
  6. T+60 · in 13d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GT Biopharma filed a Certificate of Amendment to effect a 1-for-25 reverse stock split and reduce authorized shares from 265M to 26.5M, effective September 8, 2026. The company also eliminated 11 series of preferred stock (none outstanding except Series C which was converted). This is a capital structure cleanup and Nasdaq compliance action for a micro-cap biotech with a $13M market cap, not a fundamental business event.

Key Facts

  • 1-for-25 reverse stock split effective September 8, 2026 at 12:01 a.m. ET
  • Pre-split shares: ~45,109,497 → post-split: ~1,804,379
  • Authorized shares reduced from 265,000,000 to 26,500,000 (25M common + 1.5M preferred)
  • 11 series of preferred stock eliminated via Certificates of Elimination (none were outstanding)
  • Series C Preferred Stock converted on September 2, 2026
  • New CUSIP: 36254L 407
  • Board approved final ratio of 1-for-25 on August 27, 2026, following stockholder approval on August 14, 2026

Financial Impact

No financial impact, reverse split is a mechanical share consolidation with proportional adjustments to all outstanding convertible securities, warrants, and options. No new capital raised or deployed.

shares outstandingauthorized shares

Risk Factors

  • Post-split float of ~1.8M shares creates elevated volatility and potential for sharp moves on low volume
  • Multiple active S-1 registration statements suggest potential future dilutive offerings

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 22 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (GTBP), Batch item 10001493152-26-041333
Exhibit: ex3-12.htm0001493152-26-041333
Exhibit: ex3-8.htm0001493152-26-041333
Exhibit: ex3-9.htm0001493152-26-041333
Exhibit: ex3-3.htm0001493152-26-041333
Exhibit: ex3-4.htm0001493152-26-041333
Exhibit: ex3-11.htm0001493152-26-041333
Exhibit: ex3-7.htm0001493152-26-041333
Exhibit: ex3-2.htm0001493152-26-041333
Exhibit: ex3-5.htm0001493152-26-041333
Exhibit: ex3-6.htm0001493152-26-041333
Exhibit: ex3-1.htm0001493152-26-041333
Exhibit: ex3-10.htm0001493152-26-041333
Document: 0001493152-26-041333-index-headers.html0001493152-26-041333
Document: 0001493152-26-041333-index.html0001493152-26-041333
Document: 0001493152-26-041333.txt0001493152-26-041333
8-K Filing (GTBP), Batch item 170001493152-26-041333
Exhibit: ex3-12.htm0001493152-26-041333
Exhibit: ex3-8.htm0001493152-26-041333
Exhibit: ex3-9.htm0001493152-26-041333
Exhibit: ex3-3.htm0001493152-26-041333
Exhibit: ex3-4.htm0001493152-26-041333

Track record

12 reports on GTBP

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +41.62% at T+60 after the Aug 14, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 3/10 Entry $3.72 Now $3.54 −4.97% settles Feb 12
  2. Oct 21, 202627d ago EFFECT Bearish 6/10 Entry $5.41 Now $3.54 +34.66% settles Jan 19
  3. Oct 13, 20264w ago DEF 14A Bearish 7/10 Entry $6.21 Now $3.54 +43.08% settles Jan 11
  4. Oct 9, 20265w ago S-1 Bearish 7/10 Entry $6.80 Now $3.54 +48.01% settles Jan 7
  5. Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.80 Now $3.54 −48.01% settles Dec 22
  6. Sep 15, 20268w ago 8-K Bearish 7/10 Entry $9.00 Now $3.54 +60.72% settles Dec 9
  7. Sep 3, 202610w ago 8-K Neutral 4/10 Viewing Entry $0.2524 Now $3.54 +1300.55% settles Nov 30
  8. Aug 14, 202613w ago Press Release Bearish 5/10 Entry $0.2960 to $0.1728 Now $3.54 −1094.26% ▲ +41.62% +38.58% vs SPY
  9. May 22, 202625w ago 8-K Bearish 7/10 Entry $0.4400 to $0.2754 Now $3.54 −703.41% ▲ +37.41% +40.60% vs SPY
  10. Apr 30, 202628w ago S-1 Bearish 7/10 Entry $0.3430 to $0.3167 Now $3.54 −930.61% ▲ +7.67% +10.74% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 3, 2026